Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163594 | 0.88 | HPGDS (0.42) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13851862 | 0.88 | TDP1 (0.42) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7027251 | 0.86 | MEN1 (0.45) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4867949 | 0.86 | CYP2E1 (0.43) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4871015 | 0.84 | TSHR (0.40) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL14268974 | 0.84 | TDP1 (0.41) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL14268976 | 0.84 | HTR1A (0.44) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4862725 | 0.83 | HTR1A (0.43) | TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL8086804 | 0.83 | CYP2E1 (0.58) | — | |
| SCHEMBL13851782 | 0.82 | MAPT (0.39) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130225-A1 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090130225-A1 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090130225-A1 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1960413-A2 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060618-A2 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060618-A2 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130225-A1 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | MGAM, MLX, MYCBP | TDP1 4449/4885L3MBTL1 3698/4885MAPT 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.